# A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

> **NCT00514371** · PHASE2,PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 22 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** tanespimycin
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00514371
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2015-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00514371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00514371, "A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00514371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*